Publicacións (111) Publicacións de EDDY SOTELO PEREZ

2024

  1. Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

    Biomedicine and Pharmacotherapy, Vol. 173

  2. Gemcitabine-Vitamin E Prodrug-Loaded Micelles for Pancreatic Cancer Therapy

    Pharmaceutics, Vol. 16, Núm. 1

2023

  1. A Robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery

    Molecules, Vol. 28, Núm. 24

  2. Development of Fluorescent 4-[4-(3H-Spiro[isobenzofuran-1,4′-piperidin]-1′-yl)butyl]indolyl Derivatives as High-Affinity Probes to Enable the Study of σ Receptors via Fluorescence-Based Techniques

    Journal of Medicinal Chemistry, Vol. 66, Núm. 6, pp. 3798-3817

  3. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 235-250

  4. Exploring the Effect of Halogenation in a Series of Potent and Selective A2BAdenosine Receptor Antagonists

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 890-912

  5. Fluorescence based HTS-compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells

    Frontiers in Molecular Biosciences, Vol. 10

  6. Multicomponent Reaction-Assisted Drug Discovery: A Time- and Cost-Effective Green Approach Speeding Up Identification and Optimization of Anticancer Drugs

    International Journal of Molecular Sciences, Vol. 24, Núm. 7

  7. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)

    European Journal of Medicinal Chemistry, Vol. 248

  8. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

    Biomedicine and Pharmacotherapy, Vol. 164

2022

  1. A 2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 5

  2. Enantiomeric Separation and Molecular Modelling of Bioactive 4-Aryl-3,4-dihydropyrimidin-2(1H)-one Ester Derivatives on Teicoplanin-Based Chiral Stationary Phase

    Separations, Vol. 9, Núm. 1

  3. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3Antagonists

    ACS Medicinal Chemistry Letters, Vol. 13, Núm. 2, pp. 243-249

  4. Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands

    Biomedicine and Pharmacotherapy, Vol. 153

  5. Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1Antagonists

    Journal of Medicinal Chemistry, Vol. 65, Núm. 3, pp. 2091-2106

2021

  1. 3,4-Dihydropyrimidin-2(1H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition

    Journal of medicinal chemistry, Vol. 64, Núm. 1, pp. 458-480

  2. Catalytic performance of a metal-free graphene oxide-Al2O3 composite assembled by 3D printing

    Journal of the European Ceramic Society, Vol. 41, Núm. 2, pp. 1399-1406

  3. Deciphering conformational selectivity in the A2A adenosine G protein-coupled receptor by free energy simulations

    PLoS Computational Biology, Vol. 17, Núm. 11

  4. Identification of V6.51L as a selectivity hotspot in stereoselective A2B adenosine receptor antagonist recognition

    Scientific Reports, Vol. 11, Núm. 1

  5. Potent and Subtype-Selective Dopamine D2Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach

    Journal of Medicinal Chemistry, Vol. 64, Núm. 12, pp. 8710-8726